However, in their subgroup analysis of patients with PD‐L1 tumor area positivity score of 20% or above, the mPFS was significantly longer in those patients using durvalumab compared to the placebo arm (HR 0.62, 95% CI 0.42–0.91). Here, CD274 is linked to neoplasm.